此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PliaFX Flo Subtalar Fusion Study

2026年11月16日 更新者:Alastair Younger、St. Paul's Hospital, Canada

A Prospective Pilot Comparative Study to Evaluate the Efficacy of PliaFX® Flo Allograft in Subtalar Arthrodesis at St. Paul's Hospital in Vancouver, Canada

During a subtalar fusion, the bones making up the subtalar joint (talus and calcaneus) are permanently fused together. In the procedure, any damaged cartilage and bone at the subtalar joint is removed, then screws are inserted into the joint to fuse the bones together. Depending on the surgeon, a bone graft is sometimes applied between the bones prior to screw insertion to aid in bone bridging (growth of bone into the fusion site). Participants who consent to this study and are assigned to the PliaFX® Flo Allograft group, will receive PliaFX® Flo Allograft (human tissue donated from a donor) at the fusion site. The PliaFX® Flo system is demineralized bone fibers (hard minerals removed from bone using acid) in a sterile syringe that allows for delivery into small areas where bone graft is needed to assist bone fusion. The allograft bone fibers are produced from donated human cadaver (deceased human) bone.

This study aims to determine whether the use of PliaFX® Flo Allograft in subtalar fusions will improve functioning and healing of the bone and cartilage for patients like you. Participants who are interested will discuss with their surgeon and be randomly assigned to one of the two study procedures below. The patient will not know what group they are in until after all data has been collected and all study visits are complete.

研究概览

地位

尚未招聘

研究类型

介入性

注册 (估计的)

50

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • British Colombia
      • Vancouver、British Colombia、加拿大、V6Z 1Y6
        • St. Paul's Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

19年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. The subject is at least 19 years of age.
  2. The subject is considered to be skeletally mature.
  3. The subject qualifies for subtalar fusion based on physical examination and/ or past medical history including isolated osteoarthritis, post-traumatic, degenerative, or rheumatoid arthritis of the ankle.
  4. The subject experiences severe pain in the subtalar joint that could not be cured with non-operative treatment options.
  5. The patient may undergo a subtalar fusion as part of a triple arthrodesis.
  6. The patient may have forefoot pathology addressed by either prior or concurrent surgery (osteotomies or fusions).
  7. The patient consented for either an arthroscopic or open procedure.
  8. The subject is able to comply with all post-operative evaluations and visits.
  9. The subject consents to and will receive either no graft or PliaFX® Flo allograft during their surgery

Exclusion Criteria:

  1. The subject has:

    • Severe osteoporosis
    • Neuromuscular impairment
    • Prior infection in the affected joint
  2. The subject currently has acute infections that, in the opinion of the Investigator, may complicate healing.

  3. The subject has a known or suspected allergy to any of the processing reagents listed in the packet insert (alcohol, glycinate buffer, and glycerol).

  4. The subject is renal compromised.

  5. The subject has a major risk factor for non-union (ex. poorly controlled diabetes or current smoker).

  6. The subject is undergoing a revision of a prior subtalar fusion.

  7. The subject has had a prior ankle joint fusion.

  8. An ankle joint replacement or ankle joint fusion may be performed during the same sitting.

  9. The subject has a BMI of > 50 kg/m2.

  10. The subject is known to be pregnant, or plans to become pregnant during the study period

  11. The investigator judges the subject to be unable or unlikely to remain compliant to follow-up due to a physical or mental condition (ex. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.).

  12. The subject is unable to provide informed consent.

  13. The subject is unable to communicate with the research team.

  14. The subject is unable to comply with follow-up.

  15. The subject has a history of substance addiction (e.g. recreational drugs, narcotics, or alcohol) within 12 months prior to screening for study entry

  16. The subject will be receiving a structural autograft or allograft (such as a femoral head graft or tri cortical iliac crest graft) to fill a defect greater than 1cm3

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:设备可行性
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:PliaFX Flo Allograft

Participant will receive PliaFX Flo during their Subtalar Arthrodesis procedure.

Participant will receive the PliaFX Flo Allograft during their Subtalar Arthrodesis procedure.

无干预:No Graft

Participant will receive no graft during their Subtalar Arthrodesis procedure.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Bone Bridging Percentage
大体时间:Enrollment to last Follow-up visit (52 weeks)

Bone bridging percentage measured by CT scans at 12, 24, and 52 weeks post-operatively.

Enrollment to last Follow-up visit (52 weeks)

次要结果测量

结果测量
措施说明
大体时间
Foot and Ankle Measure (FAAM) Questionnaire
大体时间:Enrollment to last follow up visit (52 weeks)

Minimum value of 0, maximum value of 100, and lower scores are worse.

Enrollment to last follow up visit (52 weeks)
Current Health Assessment Questionnaire
大体时间:Enrollment to last follow up visit (52 weeks)

Minimum value of 0, maximum value of 100, and higher scores are worse.

Enrollment to last follow up visit (52 weeks)
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
大体时间:Enrollment to last follow up visit (52 weeks)

Minimum value of 0, maximum value of 100, and lower scores are worse.

Enrollment to last follow up visit (52 weeks)
Demographics Questionnaire
大体时间:Enrollment to last follow up visit (52 weeks)
Enrollment to last follow up visit (52 weeks)
Ankle Osteoarthritis Scale
大体时间:Enrollment to last follow up visit (52 weeks)

Minimum value of 1, maximum value of 100, and higher scores are worse.

Enrollment to last follow up visit (52 weeks)
SF-36 Health Survey
大体时间:Enrollment to last follow up visit (52 weeks)
Enrollment to last follow up visit (52 weeks)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月1日

初级完成 (估计的)

2030年12月1日

研究完成 (估计的)

2031年12月1日

研究注册日期

首次提交

2026年10月5日

首先提交符合 QC 标准的

2026年10月13日

首次发布 (实际的)

2026年10月20日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • H26-01617

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅